



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 39/40, C12P 21/00 A61K 7/16	A1	(11) International Publication Number: WO 88/ 06455 (43) International Publication Date: 7 September 1988 (07.09.88)
(21) International Application Number: PCT/GB88/00135 (22) International Filing Date: 26 February 1988 (26.02.88) (31) Priority Application Number: 8704648 (32) Priority Date: 27 February 1987 (27.02.87) (33) Priority Country: GB (71) Applicant (for all designated States except US): COUNCIL OF GOVERNORS OF THE UNITED MEDICAL AND DENTAL SCHOOLS OF GUY'S AND ST. THOMAS'S HOSPITALS [GB/GB]; London SE1 (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : LEHNER, Thomas [GB/GB]; SMITH, Roberta [GB/GB]; Department of Immunology, Guy's Hospital, London SE1 9RT (GB). (74) Agents: GOLDIN, Douglas, Michael et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5EU (GB).		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANTIBODIES AGAINST STREPTOCOCCUS (57) Abstract An antibody is described against an antigenic determinant common to <i>Streptococcus sobrinus</i> serotype d and <i>Streptococcus mutans</i> serotype c. It can be produced, in monoclonal or polyclonal form, using as immunogen, <i>Streptococcus sobrinus</i> serotype d or streptococcal antigen thereof or a fragment of said antigen, said fragment retaining the antigenic determinants characteristic of <i>S. sobrinus</i> serotype d. The antibody or fragments thereof can be used to combat dental caries.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

- 1 -

TITLE : ANTIBODIES AGAINST STREPTOCOCCUS

FIELD OF THE INVENTION

THIS INVENTION relates to antibodies useful to combat dental caries.

BACKGROUND TO THE INVENTION

5 Streptococcus mutans has been recognised for many years as the major organism responsible for the development of dental caries in mammals. Various vaccines have been proposed in the past based on various antigenic fragments of S. mutans. One such vaccine is described in
10 British Patent No. 2,060,647 based upon the antigen known as I or I/II. Antigen I has a molecular weight, as determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) of 146-155 Kd. Antigen I/II is believed to be a conjugate of antigen I and antigen II,
15 this I/II antigen having a molecular weight determined by SDS-PAGE of 175-195 Kd. Published European Patent Application No. EP-A-0 116 472 describes antigen X which is a much smaller molecule having a molecular weight, determined by SDS-PAGE of about 3.5-4.5 Kd but which
20 appears to include the same antigenic determinants included within antigens I and I/II.

- 2 -

Antibodies against antigens I, I/II and X are known. The above-mentioned British Patent describes the raising of antibodies against antigens I and I/II by conventional procedures in experimental animals, for example rhesus monkeys, rabbits and mice. These antibodies are proposed primarily for the purification of the antigen by affinity chromatography but the Patent Specification mentions the possibility of using such antibodies for passive immunisation by conventional means.

10 Conventional passive immunisation involves parenteral administration of the antibodies but while such techniques are theoretically available, as a practical matter, passive immunisation has never been regarded as clinically attractive and indeed, the British Patent refers to the

15 preferred use of the antigenic materials for direct immunisation.

All antibodies that have been raised against S. mutans serotype c or against the streptococcal antigen serotype c (SA_c) exhibit a certain degree of cross-

20 reactivity. It is well known that such antibodies are also cross-reactive with antigenic material originating from serotypes e and f of S. mutans. In clinical practice, it is found that serotypes c, e and f amount to about 90% of the bacterial S. mutans population so that

25 the prophylactic or therapeutic use of antibodies raised

- 3 -

against serotype c are of considerable practical value but fail to be effective in relation to the residual approximately 10% of the bacterial population. In some series serotype d is found in addition to serotype c in up to 50% of children examined.

This residual 10% is comprised predominantly of a serotype d that until very recently has been regarded merely as another serotype of S. mutans. However recently, this particular serotype has been reclassified as S. sobrinus and, in the description of this invention, we will use the nomenclature S. sobrinus serotype d rather than S. mutans serotype d.

We have now found that if antibodies are raised against S. sobrinus serotype d, that many of the resulting antibodies are cross-reactive not only with S. sobrinus serotype d and also S. sobrinus (S. mutans) serotype g (and serotype a) but surprisingly, that such antibodies are also cross-reactive with serotypes c, e and f of S. mutans. Since somewhere of the order of 98% of all serotypes of S. mutans/S. sobrinus found in the oral cavities are of serotypes a, c, d, e, f and g, our discovery has enabled us to produce, for the first time, antibodies having the potential for prophylactic and/or therapeutic use in relation to substantially 100% of oral bacteria of S. mutans/S. sobrinus type that are responsible for dental caries.

- 4 -

Accordingly, the present invention provides antibodies against a common determinant of S. sobrinus serotypes d and S. mutans serotype c.

The antibodies of the present invention extend not only to whole antibodies but also to antibody
5 fragments containing the necessary binding sites to enable them to recognise and bind with the streptococcal antigen and the antibodies or fragments thereof may be prepared in polyclonal or monoclonal form.

The antibodies of the invention can be raised
10 using S. sobrinus serotype d or streptococcal antigen derived therefrom as the immunogen. Normally, the immunogen will comprise the naturally-occurring streptococcal antigen but, as is the case with the use of streptococcal antigen from serotype c of S. mutans, use
15 can also be made of antigenic fragments of serotype d, provided that those antigenic fragments contain the necessary antigenic determinants characteristic of serotype d.

For the production of polyclonal antibodies,
20 conventional methods may be used involving the immunisation of animals with the serotype d immunogen followed by recovery of the antibodies from the blood of the immunised animals. Conventional antibody recovery methods can be used and conventional antibody purification
25 methods can be used, e.g. affinity chromatography using purified immunogen or fragments thereof.

- 5 -

Where monoclonal antibodies are to be raised, the immunogen derived from serotype d can be used conventionally to immunise mice or other mammals and the spleen of the immunised mammal hybridised with myeloma cells to produce a population of hybridoma cells. Alternatively, immunogen derived from serotype d can be used for in vitro stimulation of B-lymphocytes and the stimulated B-lymphocytes then hybridised with myeloma cells by methods known per se to provide a population of hybridomas. The resulting population of hybridomas may then be screened to select those secreting monoclonal antibody that is cross-reactive by S. sobrinus serotype d and S. mutans serotype c. When polyclonal antibodies are produced, they may also be screened to select those showing the serotype d/c cross-reactivity. The antibodies, however produced, can be purified if necessary by affinity chromatography techniques or by staphylococcal protein A to separate IgG class of antibodies or by using serotype d antigen.

Where antibody fragments are required, the polyclonal or monoclonal antibody produced by the methods described above can be fragmented by digestion with papain or pepsin by conventional methods.

DETAILED DESCRIPTION OF THE INVENTION

While the present invention is directed primarily to humans, the problem of dental caries is not confined to humans but arises in other mammals including

- 6 -

non-human primates, domestic and farm animals and particularly in those cases where the non-human mammal eats a substantial proportion of food including sugars.

The monoclonal antibodies used in this invention
5 may be applied to the tooth in the mouth of the mammal by any convenient method. Numerous methods are now available for the treatment of teeth with various materials for various purposes. If the treatment is to be carried out by a Dental Surgeon, then the monoclonal antibody is
10 conveniently applied by painting the surface of the tooth. If the monoclonal antibodies are to be self-applied, then the monoclonal antibodies may be included in a toothpaste, mouthwash, chewing gum, lozenge or gel. As will be described in more detail below, the duration of protection
15 afforded by the method of the present invention is surprisingly long but the frequency of the topical application is primarily one for the users personal convenience. Methods of self-application from toothpastes etc., can result in applications being repeated perhaps
20 daily while the use of lozenges can result in more frequent application of the antibody. Chewing gums and gels may be regarded, for this purpose, as providing a certain amount of sustained release of the antibody over a period of half-an-hour or more and indeed, if sustained
25 release of the antibody is required, then appropriate formulations can be used that will result in slow release

- 7 -

of antibody into the mouth from the formulation as a result of the temperature or saliva conditions etc., found in the mouth. In certain instances, it may be desirable to provide a more formal prolonged contact of the antibody
5 with the tooth surface and in such cases, appropriate dental trays can be used that will cover the tooth after it has been coated with antibody and prevent the antibody from being removed, e.g. by saliva, for a predetermined period.

10 It is important that the antibody be brought into contact with the surface of the tooth and ideally should be applied to all of the smooth and occlusal surfaces of the tooth. It is not detrimental for the antibody to contact the gum but the protection afforded by
15 the present invention does appear to result primarily if not exclusively from the contact of the antibody with the surface of the tooth itself.

Topical administration of the antibodies is the most practical course for self-administration.

20 The exact amount of antibody that is applied does not appear to be critical since, in a method of this type, repeated self-application of antibody is not difficult and indeed, particularly after initial treatment by a Dental Surgeon, maintenance or top-up treatment can
25 be carried out by the user at whatever frequency is desirable. By way of guidance, it can be indicated that

- 8 -

somewhere of the order of 10 to 100 micrograms of antibody
can be applied to each tooth on each occasion that
antibody is applied but amounts of antibody outside this
range can certainly be applied without causing detriment
5 to the subject. The use of insufficient quantities of
antibody simply means that the level of protection is not
as great as would otherwise be obtainable while the use of
excessive amounts of antibody does not improve the
protection and simply results in unnecessary use of
10 antibody.

The exact formulation for the antibody is not a
matter of critical importance but depends entirely upon
the method of application to be adopted and the
convenience of the user. In all cases, it is important to
15 formulate the antibody in an environment of appropriate pH
and which is free from other deleterious materials which
might bring about protein degradation and the formulation
should, of course, also be free from microbial impurity
that would be deleterious in the subject's mouth. For
20 example, for use in the dental surgery, the antibody could
be formulated as a simple aqueous dispersion containing
somewhere in the region of 0.1 to 10 milligrams of
antibody per 100 microlitres of liquid and a liquid of
such concentration could be applied to the tooth at the
25 rate of about 1 to 10 microlitres of dispersion per tooth.
Where the antibody is to be formulated for

- 9 -

self-administration, then the concentration can be selected bearing in mind the above guidelines, the quantities of the formulation that are normally taken on each occasion of self-administration and the fact that
5 over administration of antibody will not be deleterious.

The following Examples are given to illustrate the invention.

Materials and Methods

Organisms

10 S. mutans serotypes and strains were obtained from a number of laboratories as described previously (Smith, Lehner, Beverley, 1984). Samples of serotype d strains (FRID and Lee) were isolated in our laboratories. Strain AHT, originally described as serotype a however,
15 has been apparently reclassified to serotype g; hence no results are presented for serotype a.

Streptococcal antigens (SA)

SA from serotype d (strains FRID and OMZ 176) were prepared from culture supernatants by combination of
20 ammonium sulphate precipitation, ion exchange chromatography and gel filtration, as described previously (Russell et al 1980). Antigen dI/II, equivalent to cI/II

- 10 -

of serotype c (185 Kd) was characterised using cross-reactive polyclonal rabbit antisera to SA cI/II.

Production of monoclonal antibodies (McAb)

McAb to SA dI/II were prepared by a method similar to that of Smith et al 1984 following the procedure of Fazekas de St. Groth and Scheidegger (1980). Briefly Balb c mice were immunised with 10 ug SA dI/II (strain FRID) intraperitoneally in Freund's complete adjuvant, followed two weeks later by 10 ug SA dI/II in Freund's incomplete adjuvant. The third and final injection, again two weeks later was given intravenously in saline and the mouse was bled and sacrificed four days later and the spleen was removed. Immune mouse spleen cells were fused at a ratio of 1:1 with the mouse myeloma line P3-NS1/1-Ag4-1 (NS1), in the presence of 50% (wt/vol) polyethylene glycol (PEG 4000 d; Sigma chemical Co.) in RPMI 1640 (Gibco Laboratories). The PEG was neutralised with 10N sodium hydroxide prior to use.

After fusion the cells were plated out at 2×10^5 total viable cells per well, in 24 well cluster plates (Costar plastics, Cambridge, Mass.). Feeder cells from peritoneal lavage of BALB/c mice were added at 3×10^4 cell/well. Throughout cloning, RPMI 1640, supplemented

- 11 -

with 10% foetal calf serum, glutamine (2mM), pyruvate (1mM) and antibiotics was used. For the first two weeks after fusion the medium was further supplemented with hypoxanthine, aminopterin and thymidine to eliminate unfused NS1 cells. By the third week only hypoxanthine and thymidine were added. After 10 to 14 days the supernatants of wells showing growth were assayed for specific antibodies to the purified SA and to heart homogenate (Bergmeier and Lehner 1983) in a micro-solid-phase radioassay, as described previously (Smith et al 1984). Cultures giving binding greater than 3 times the background were cloned, at least twice by the method of limiting dilution to 0.3 cells per well and dispensed in the presence of 5×10^3 feeder cells and 5×10^4 normal spleen cells, into 96-well plates, with flat bottom wells (Costar). Cloned cells were expanded and then injected into pristane primed mice for ascites. Culture supernatants were stored at 4°C with 0.1% sodium azide and ascites at -20°C. The cells were frozen in the presence of 10% dimethyl sulphoxide, 50% foetal calf serum in RPMI 1640 and stored in liquid nitrogen.

Characterisation of the McAb

The isotype of the McAb was determined by double diffusion precipitation in 1% agarose, using culture supernatants of the McAb and reactions with commercial

- 12 -

antisera (Nordic) for IgG1, IgG2a and (Eivai Bios) for IgM. The specificity of the McAb was tested by titrating each McAb against purified SA dI/II, derived from S. sobrinus serotype d (FRID, OMZ 176) or S. mutans serotype c (Guy's strain) as well as against whole cells of the other serotypes and S. sanguis (OMZ 9), by the radioassay (Smith et al 1984).

Inhibition studies of McAb with purified SA for antigen specificity

Ascitic fluids of the McAb were diluted with PBS containing 0.5% bovine serum albumin and 0.05% Tween 20, to give approximately 50% binding to SA dI/II (FRID) by micro-solid-phase radioassay. 200 μ l samples of dilute McAb were incubated with 5 μ g of SA dI/II (FRID), or saline overnight at 4°C. The samples were then examined by the radioassay for antibody binding to SA dI/II.

- 13 -

ResultsCharacterisation of McAbTABLE 1

	Code	<u>Strep. mutans</u> antigen specificity	Antibody class	Serotype specificity
5	Guy's 1	serotype c I/III	IgG2a	c, e, f
	Guy's 11	serotype c I/II & d I/II	IgG2b	a,c,d,e,f,g
	Guy's 12	serotype c I/II & d I/II	IgG1	c,d,e,f,g
	Guy's 13	serotype c I/II & d I/II	IgG1	a,c,d,e,f,g

serotype h not tested

10 We have prepared and characterised various
monoclonal antibodies (McAb) against various SA from
serotype c and d (Table 1). Guy's 1 (formerly 2D4), was
prepared using the antigen for which it is specific as
immunogen. McAb to SA dI/II, Guy's 11, 12 and 13 were
15 derived from a single fusion, using SA dI/II (FRID) as
immunogen. The McAb belong to IgG1, IgG2a and IgM class
as shown in Table 1.

 Ascitic fluid of the McAb titrate to $>10^{-6}$, as
measured by the radioassay against SA dI/II for Guy's 11,
20 12, 13 or SA cI/II for Guy's 1. Similarly, using the

- 14 -

fluid phase radioassay against whole cells of S. mutans, the McAb which bind to SA dI/II also bind in high titres ($>10^{-6}$) to the cell surface of serotype d (OMZ 176). Guy's 1, equivalent to SA cI/II, also shows titres of $>10^{-6}$ against the whole cells of serotype c (Guy's).

SA specificity

The specificity of McAb Guy's 1 has been demonstrated previously for SA cI/II, I, II and III by direct binding and competitive inhibition in the radioassay. Examination of the binding of Guy's 1 to SA dI/II was negative. However, Guy's 11, 12 and 13 react with SA I/II derived from both S. mutans and S. sobrinus.

Serotype specificity

Binding of McAb to the surface of different serotypes of S. mutans and S. sobrinus was examined by the fluid phase radioassay against whole cells. Guy's 1 bound to the surface of serotype c (Guy's strain) and cross-reacted with serotype f (OMZ 175). It also showed low but significant binding to serotype e, giving the classical serotype cross-reactions for S. mutans (c, e, f). Guy's 11, 12 and 13 reacted with S. mutans serotypes,

- 15 -

c, e, f and a (except 12) and S. sobrinus serotypes d and g. None of the McAb gave any significant binding to S. sanguis.

We have prepared McAb which are specific for

5 S. mutans serotypes c, e and f and S. sobrinus serotypes d and g. McAb to S. mutans or S. sobrinus are of the IgG1 and IgG2a classes but S. sobrinus also elicited McAb of the IgM class. We have demonstrated the specificity of McAb for cell surface SA I/II, I, II or III by direct

10 binding and competitive inhibition. McAb reacting to serotype cI/II do not bind to serotype dI/II but the three monoclonal antibodies raised by immunisation with S. sobrinus showed a broad reactivity with S. mutans and S. sobrinus serotypes. This suggests that Guy's 11, 12 and

15 13 are most likely directed against a common determinant of the mutans type of streptococci and are therefore particularly convenient reagents to be used against colonisation of S. mutans and S. sobrinus. These SA are expressed on the cell surface (Zanders and Lehner 1981,

20 Moro and Russell 1985) and are here shown to bind strongly McAb in a fluid phase radioassay. The McAb show high titres ($>10^{-6}$), in binding both to purified SA and to the SA on the cell surface.

REFERENCES

1. Bergmeier L.A. and T. Lehner. 1983. Infect. Immun. 40:1075-1082.
2. Fazekas de St. Groth S. and D. Scheidegger. 1980. J. Immunol. Methods 35:1-21.
3. Moro I. and M.W. Russell. 1983. Infect. Immun. 41:410-413.
4. Russell, M.W., L.A. Bergmeier, E.D. Zanders and T. Lehner. 1980. Infect. Immun. 28:486-493.
5. Russell, M.W., L.A. Bergmeier, E.D. Zanders and T. Lehner. 1980. Infect. Immun. 29:999-1006.
6. Smith, R., T. Lehner and P.C.L. Beverley. 1984. Infect. Immun. 46:168-175.
7. Zanders E.D., and T. Lehner. 1981. J. Gen. Microbiol. 122:217-225.

- 17 -

CLAIMS

1. An antibody against an antigenic determinant common to Streptococcus sobrinus serotype d and Streptococcus mutans serotype c.
2. An antibody obtained using as immunogen,
5 Streptococcus sobrinus serotype d or streptococcal antigen thereof or a fragment of said antigen, said fragment retaining the antigenic determinants characteristic of S. sobrinus serotype d.
3. A polyclonal antibody according to claim 1
10 or 2.
4. A monoclonal antibody according to claim 1 or 2.
5. A fragment of an antibody according to any one of the preceding claims, said fragment retaining sites
15 that bind with both S. sobrinus serotype d and S. mutans serotype c.
6. An antibody or fragment thereof of the IgG1 or IgG2b class.

- 18 -

7. A dental composition, suitable for topical application to the teeth and/or gums, comprising an antibody or fragment thereof according to any one of the preceding claims together with a carrier or diluent.

5 8. A composition according to claim 7 in the form of a toothpaste, mouthwash, chewing gum, lozenge or gel.

9. A method of combatting dental caries in a mammal which comprises applying to the teeth and/or gums
10 of the mammal an antibody or fragment thereof according to any one of claims 1 to 6 or a composition according to claim 7 or 8.

10. An antibody or fragment thereof according to any one of claims 1 to 6 or a composition according to
15 claim 7 or 8 for use in a method of combatting dental caries in a mammal.

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/GB 88/00135**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : A 61 K 39/40; C 12 P 21/00; A 61 K 7/16																							
II. FIELDS SEARCHED <div style="text-align: right; margin-right: 100px;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 25%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; vertical-align: top;">IPC ⁴</td> <td style="border: none; vertical-align: top;">A 61 K, C 12 P, A 23 G</td> </tr> </table> <div style="text-align: center; margin-top: 10px;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ </div>			Classification System	Classification Symbols	IPC ⁴	A 61 K, C 12 P, A 23 G																	
Classification System	Classification Symbols																						
IPC ⁴	A 61 K, C 12 P, A 23 G																						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border: none;"> <tr> <th style="width: 10%; border: none;">Category ¹⁰</th> <th style="width: 70%; border: none;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; border: none;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: none; vertical-align: top;">A</td> <td style="border: none;">EP, A, 0116472 (COUNCIL OF GOVERNORS OF THE UNITED MEDICAL AND DENTAL SCHOOL OF GUY'S AND ST. THOMAS'S HOSPITALS) 22 August 1984 --</td> <td style="border: none;"></td> </tr> <tr> <td style="border: none; vertical-align: top;">A</td> <td style="border: none;">WO, A, 81/01101 (LEHNER et al.) 30 April 1981 (cited in the application) --</td> <td style="border: none;"></td> </tr> <tr> <td style="border: none; vertical-align: top;">A</td> <td style="border: none;">GB, A, 2167299 (LION CORP.) 29 May 1986 --</td> <td style="border: none;"></td> </tr> <tr> <td style="border: none; vertical-align: top;">A</td> <td style="border: none;">EP, A, 0140498 (LION CORP.) 8 May 1984 --</td> <td style="border: none;"></td> </tr> <tr> <td style="border: none; vertical-align: top;">A</td> <td style="border: none;">Chemical Abstracts, vol. 103, no. 17, 28 October 1985 (Columbus, Ohio, US), C.P. Mallett et al.: "Anti-Streptococcus mutants ribosome monoclonal antibodies recognize a cell surface antigen on different serotypes", see page 558, abstract no. 139998v, & Curr.Microbiol. 1985, 12(2), 117-20 --</td> <td style="border: none;"></td> </tr> <tr> <td style="border: none; vertical-align: top;">A</td> <td style="border: none;">Infection and Immunity, vol. 46, no. 1, R. Smith et al.: "Characterization of monoclonal antibodies to Streptococcus mutans antigenic determinants I/II,</td> <td style="border: none;"></td> </tr> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	EP, A, 0116472 (COUNCIL OF GOVERNORS OF THE UNITED MEDICAL AND DENTAL SCHOOL OF GUY'S AND ST. THOMAS'S HOSPITALS) 22 August 1984 --		A	WO, A, 81/01101 (LEHNER et al.) 30 April 1981 (cited in the application) --		A	GB, A, 2167299 (LION CORP.) 29 May 1986 --		A	EP, A, 0140498 (LION CORP.) 8 May 1984 --		A	Chemical Abstracts, vol. 103, no. 17, 28 October 1985 (Columbus, Ohio, US), C.P. Mallett et al.: "Anti-Streptococcus mutants ribosome monoclonal antibodies recognize a cell surface antigen on different serotypes", see page 558, abstract no. 139998v, & Curr.Microbiol. 1985, 12(2), 117-20 --		A	Infection and Immunity, vol. 46, no. 1, R. Smith et al.: "Characterization of monoclonal antibodies to Streptococcus mutans antigenic determinants I/II,	
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																					
A	EP, A, 0116472 (COUNCIL OF GOVERNORS OF THE UNITED MEDICAL AND DENTAL SCHOOL OF GUY'S AND ST. THOMAS'S HOSPITALS) 22 August 1984 --																						
A	WO, A, 81/01101 (LEHNER et al.) 30 April 1981 (cited in the application) --																						
A	GB, A, 2167299 (LION CORP.) 29 May 1986 --																						
A	EP, A, 0140498 (LION CORP.) 8 May 1984 --																						
A	Chemical Abstracts, vol. 103, no. 17, 28 October 1985 (Columbus, Ohio, US), C.P. Mallett et al.: "Anti-Streptococcus mutants ribosome monoclonal antibodies recognize a cell surface antigen on different serotypes", see page 558, abstract no. 139998v, & Curr.Microbiol. 1985, 12(2), 117-20 --																						
A	Infection and Immunity, vol. 46, no. 1, R. Smith et al.: "Characterization of monoclonal antibodies to Streptococcus mutans antigenic determinants I/II,																						
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>																							
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> Date of the Actual Completion of the International Search 2nd June 1988 </td> <td style="width: 50%; border: none; vertical-align: top;"> Date of Mailing of this International Search Report 15 JUL. 1988 </td> </tr> <tr> <td style="border: none; vertical-align: top;"> International Searching Authority EUROPEAN PATENT OFFICE </td> <td style="border: none; vertical-align: top;"> Signature of Authorised Officer P.C.G. VAN DER PUTTEN </td> </tr> </table>			Date of the Actual Completion of the International Search 2nd June 1988	Date of Mailing of this International Search Report 15 JUL. 1988	International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorised Officer P.C.G. VAN DER PUTTEN																	
Date of the Actual Completion of the International Search 2nd June 1988	Date of Mailing of this International Search Report 15 JUL. 1988																						
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorised Officer P.C.G. VAN DER PUTTEN																						

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
	I,II, and III and their serotype specificities", pages 168-175 -----	

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 8800135
SA 20940

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 04/07/88
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0116472	22-08-84	JP-A- 59219238 US-A- 4594244	10-12-84 10-06-86
WO-A- 8101101	30-04-81	GB-A, B 2060647	07-05-81
GB-A- 2167299	29-05-86	JP-A- 61112028 DE-A- 3539202 US-A- 4725428	30-05-86 22-05-86 16-02-88
EP-A- 0140498	08-05-85	JP-A- 60038329 US-A- 4693888	27-02-85 15-09-87